Donafenib is a targeted therapy derived from the structural optimization of sorafenib, capable of inhibiting the activity of multiple targets, including VEGFR, PDGFR, and RAF, thereby preventing tumor growth and angiogenesis [128]. The gene discussed is KDR; the disease is neoplasm.